Learn more about whether BioMarin Pharmaceutical Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Scientists found a virus-like living entity in human bodies named "obelisks" - small loops of RNA, each a thousand genetic ...

Vishal Mukund Sonje, Vaccine Manufacturing Lead, CEPI, talks about the challenges that arise in the manufacturing of vaccines ...

Traditional breeding and genetic modification methods have struggled to keep pace with the rapid evolution of plant viruses.

Biopharma has finally begun catching up with the overall stock market, as shares of the top three biopharma exchange traded funds (ETFs) jumped well into double digits over the past six months.

Ebola is one of the nasty viruses that can hide in the body even after a patient recovers and tests negative. It can reemerge ...

A study used advanced machine learning models to estimate that over 51 lakh Indians could be affected annually ...

Despite the recent attention to the potential of developing and using gene therapy to treat several diseases, the therapy was ...

In 2024, Molecular-Based Therapies dominated the landscape with 45.1% market share, translating to approximately US $988 ...

Significant advancements in gene silencing and gene editing offer new hope for treating rare disorders. Techniques like RNA ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...